RE: TedB14 Jun 2019 10:20
Hi seeingtom,
There will be no takeover before FDA approval, that is for sure. If you are hanging your hat on that hook, you will be very much mistaken. You seriously think that a third party company would invest say £250m up front cash before studies were complete and FDA approval obtained? What would be the career of the person doing that deal be if the studies brought further issues / delays or if FDA approval was not obtained shortly thereafter. Terminated. Also, it is far too speculative (if not unlikely) a possibility in the near term, to form any proper investment case.
Partnership, yes that is possible, but why would it involve significant up front funds before FDA approval. That wouldn't make sense from the partner's perspective. A partnership is much more likely once the FDA application is lodged / approved. In any event, unless you know something sensitive that has not been told to the market, how could you as a shareholder possibly rely upon this taking place sooner??
I did not say no near term news. You have misread my post. I stated no core commercial data, until the further studies are complete later this year and the reference to news was in that context. Yes they could come out with further mouse study or spiked blood studies. That may have a temporary impact on the share price, but AGL has been publishing such data for many years now. The only thing that really matters this year / next year is the successful ovarian and breast cancer clinical / analytical studies, which might lead to FDA approval. Look at AGL's market cap. It is priced for commerciality, not early stage non-commercial studies.
As for fetal studies, possible, but ANGLE need around £11m per year. One cannot rely on a fetal deal, but even if struck, it will not generate sufficient funds. They have only done a small scale pilot study. Remember, even much larger clinical studies in ovarian and breast have not yet generated a deal, so why would fetal generate something very large at this stage?
All in all, in my view, only the clinical study results and FDA approval will generate the sort of partnering deals that you are discussing, and we will not get to the next stage of that for several months. Yes, there may be "news" coming out before, but nothing to transform this into a 100p company. Money in AIM is hot. People will chase other dreams first and come back here later in the year. This is a fact that you cannot ignore, because you can see this actually happening in the share price in recent days / weeks.